[
  {
    "ts": null,
    "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=8d4210e22da8c29c5c039def1d203dd8af086a94e341b1f38cbc5acb48902710",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737649800,
      "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "id": 132459902,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=8d4210e22da8c29c5c039def1d203dd8af086a94e341b1f38cbc5acb48902710"
    }
  },
  {
    "ts": null,
    "headline": "Abbott reports Q4 adjusted EPS $1.34, consensus $1.34",
    "summary": "Reports Q4 revenue $11B, consensus $11.03B. “We finished the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest of the year,” said Robert B. Ford, chairman and chief executive officer, Abbott (ABT). “We continued our track record for delivering on our commitments by achieving the upper end of our initial guidance ranges for 2024 and are well-positioned to deliver another year of strong growth in 2025.” Published first on TheFly – the",
    "url": "https://finnhub.io/api/news?id=3900efef9cf83bf611be2a8ea3019d3caf4944f453e2771e82d1e44026cd59a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737633970,
      "headline": "Abbott reports Q4 adjusted EPS $1.34, consensus $1.34",
      "id": 132473302,
      "image": "https://media.zenfs.com/en/tipranks_452/2711137b7b57c13bfec3b68ab3c5e6f8",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Reports Q4 revenue $11B, consensus $11.03B. “We finished the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest of the year,” said Robert B. Ford, chairman and chief executive officer, Abbott (ABT). “We continued our track record for delivering on our commitments by achieving the upper end of our initial guidance ranges for 2024 and are well-positioned to deliver another year of strong growth in 2025.” Published first on TheFly – the",
      "url": "https://finnhub.io/api/news?id=3900efef9cf83bf611be2a8ea3019d3caf4944f453e2771e82d1e44026cd59a8"
    }
  },
  {
    "ts": null,
    "headline": "My Top 5 Stocks to Buy in Early 2025",
    "summary": "It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term.  The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game-changing technologies to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors.  If you select quality companies and diversify across these themes of growth and security, your portfolio could shine during any market environment -- and, most importantly, offer you solid returns over the long term.",
    "url": "https://finnhub.io/api/news?id=2020214e863aeebfaea1b248360540735f5093ab4a7d962e3a8a308ad804cc77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737623700,
      "headline": "My Top 5 Stocks to Buy in Early 2025",
      "id": 132473303,
      "image": "https://g.foolcdn.com/editorial/images/804658/happy-person-at-laptop-success-winning-fists-up-victory-yes.jpg",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term.  The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game-changing technologies to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors.  If you select quality companies and diversify across these themes of growth and security, your portfolio could shine during any market environment -- and, most importantly, offer you solid returns over the long term.",
      "url": "https://finnhub.io/api/news?id=2020214e863aeebfaea1b248360540735f5093ab4a7d962e3a8a308ad804cc77"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)",
    "summary": "Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.",
    "url": "https://finnhub.io/api/news?id=436686b39cd05b9e2c1947bd2ffa52fae2aa48c38add69f294cc3313c552faf2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737621000,
      "headline": "Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)",
      "id": 132448509,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343146/image_1181343146.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.",
      "url": "https://finnhub.io/api/news?id=436686b39cd05b9e2c1947bd2ffa52fae2aa48c38add69f294cc3313c552faf2"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Q4 2024 Earnings Call Highlights: Strong Growth Across Key Segments ...",
    "summary": "Abbott Laboratories (ABT) reports robust sales growth and improved margins, setting the stage for continued success in 2025 despite market challenges.",
    "url": "https://finnhub.io/api/news?id=e730b9dfec4575f21aa6541d85e9adff5521e96d92c0d7c55153d97786a5054c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737615814,
      "headline": "Abbott Laboratories (ABT) Q4 2024 Earnings Call Highlights: Strong Growth Across Key Segments ...",
      "id": 132473304,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/9a2ddef3b4351c43bbce5b5fce83da7c",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) reports robust sales growth and improved margins, setting the stage for continued success in 2025 despite market challenges.",
      "url": "https://finnhub.io/api/news?id=e730b9dfec4575f21aa6541d85e9adff5521e96d92c0d7c55153d97786a5054c"
    }
  },
  {
    "ts": null,
    "headline": "Q4 2024 Abbott Laboratories Earnings Call",
    "summary": "Q4 2024 Abbott Laboratories Earnings Call",
    "url": "https://finnhub.io/api/news?id=88d9365d5a61a6a4731979fde88daa1085d0eb2b703e7ed63650b2cfbbe4cda1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737613597,
      "headline": "Q4 2024 Abbott Laboratories Earnings Call",
      "id": 132473305,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Q4 2024 Abbott Laboratories Earnings Call",
      "url": "https://finnhub.io/api/news?id=88d9365d5a61a6a4731979fde88daa1085d0eb2b703e7ed63650b2cfbbe4cda1"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Reports Fourth-Quarter and Full-Year 2024 Results, Issues 2025 Financial Outlook",
    "summary": "ABBOTT PARK - Abbott today announced financial results for the fourth quarter ended Dec. 31, 2024.Fourth-quarter sales increased 7.2 percent on a reported basis, 8.8 percent on an organic basis, and...",
    "url": "https://finnhub.io/api/news?id=4ae80c14e345ef7243ae767f141bcf82e8d172f93457fecf9c835176e9185283",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737611355,
      "headline": "Abbott Reports Fourth-Quarter and Full-Year 2024 Results, Issues 2025 Financial Outlook",
      "id": 132447473,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "ABBOTT PARK - Abbott today announced financial results for the fourth quarter ended Dec. 31, 2024.Fourth-quarter sales increased 7.2 percent on a reported basis, 8.8 percent on an organic basis, and...",
      "url": "https://finnhub.io/api/news?id=4ae80c14e345ef7243ae767f141bcf82e8d172f93457fecf9c835176e9185283"
    }
  }
]